Literature DB >> 17186505

Triage of women with ASCUS and LSIL cytology: use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia.

Nicolas Wentzensen1, Christine Bergeron, Frederic Cas, Svetlana Vinokurova, Magnus von Knebel Doeberitz.   

Abstract

BACKGROUND: The identification of a small percentage of high-grade cervical intraepithelial neoplasias (HGCIN) among patients with minor cytological abnormalities (atypical squamous cells of undetermined significance [ASCUS] and/or low-grade squamous intraepithelial lesions [LSIL] group) is a major problem in cytology-based cervical cancer screening. The authors investigated the efficacy of p16INK4a as a biomarker to identify samples of patients with HGCIN among those with an ASCUS or LSIL result in Papanicolaou cytology.
METHODS: Consecutive liquid-based cytology specimens of 137 ASCUS and 88 LSIL results were selected from gynecologists who adopted a triage regimen with biopsy under colposcopy 2 months later, independent of the p16INK4a result. p16INK4a stained slides were prepared and independently read by 2 observers, who used a recently described score to categorize p16INK4a stained squamous cells. The endpoint of the study was detection of a biopsy-confirmed HGCIN.
RESULTS: The overall sensitivity and specificity of p16INK4a positive cells with a nuclear score >2 for diagnosis of HGCIN in ASCUS and LSIL cases combined was 96% and 83%, respectively. The sensitivity and specificity in the ASCUS group was 95% and 84%, and 100% and 81% in the LSIL group, respectively. Two observers had a high concordance in assessing p16INK4a stained cells (kappa value of 0.841).
CONCLUSIONS: These data suggested that the use of p16INK4a as a biomarker combined with nuclear scoring of p16INK4a positive cells in cervical cytology to triage ASCUS and/or LSIL cases allows identification of HGCIN with good sensitivity and specificity. (c) 2006 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17186505     DOI: 10.1002/cncr.22420

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

Review 1.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

2.  Dual staining for p16/Ki67 is a more specific test than cytology for triage of HPV-positive women.

Authors:  Carolina Areán-Cuns; Maria Mercado-Gutiérrez; Irene Paniello-Alastruey; Fermín Mallor-Giménez; Alicia Córdoba-Iturriagagoitia; Maria Lozano-Escario; Mercedes Santamaria-Martínez
Journal:  Virchows Arch       Date:  2018-08-09       Impact factor: 4.064

3.  Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study.

Authors:  Anne Szarewski; David Mesher; Louise Cadman; Janet Austin; Lesley Ashdown-Barr; Linda Ho; George Terry; Stuart Liddle; Martin Young; Mark Stoler; Julie McCarthy; Corrina Wright; Christine Bergeron; W P Soutter; Deirdre Lyons; Jack Cuzick
Journal:  J Clin Microbiol       Date:  2012-03-14       Impact factor: 5.948

Review 4.  p16INK4a immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities: a systematic review and meta-analysis.

Authors:  Jolien Roelens; Miriam Reuschenbach; Magnus von Knebel Doeberitz; Nicolas Wentzensen; Christine Bergeron; Marc Arbyn
Journal:  Cancer Cytopathol       Date:  2012-06-14       Impact factor: 5.284

5.  Prediction of clinical outcome using p16INK4a immunocytochemical expression in low-grade squamous intraepithelial lesions and high-risk HPV-positive atypical squamous cells of undetermined significance in patients with and without colposcopic evident cervical disease.

Authors:  Ankica Lukic; Giorgio Sbenaglia; Elisabetta Carico; Matilde DI Properzio; Enrico Giarnieri; Antonio Frega; Flavia Nobili; Massimo Moscarini; Maria Rosaria Giovagnoli
Journal:  Exp Ther Med       Date:  2011-07-01       Impact factor: 2.447

6.  Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia.

Authors:  Lisa Mirabello; Mark Schiffman; Arpita Ghosh; Ana C Rodriguez; Natasa Vasiljevic; Nicolas Wentzensen; Rolando Herrero; Allan Hildesheim; Sholom Wacholder; Dorota Scibior-Bentkowska; Robert D Burk; Attila T Lorincz
Journal:  Int J Cancer       Date:  2012-08-20       Impact factor: 7.396

7.  Optimizing technology for cervical cancer screening in high-resource settings.

Authors:  Lyndsay A Richardson; Joseph Tota; Eduardo L Franco
Journal:  Expert Rev Obstet Gynecol       Date:  2011-05

Review 8.  How to evaluate emerging technologies in cervical cancer screening?

Authors:  Marc Arbyn; Guglielmo Ronco; Jack Cuzick; Nicolas Wentzensen; Philip E Castle
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

Review 9.  p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis.

Authors:  I Tsoumpou; M Arbyn; M Kyrgiou; N Wentzensen; G Koliopoulos; P Martin-Hirsch; V Malamou-Mitsi; E Paraskevaidis
Journal:  Cancer Treat Rev       Date:  2009-03-03       Impact factor: 12.111

Review 10.  Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia.

Authors:  Kate Cuschieri; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-10       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.